Extrait

The objective is to identify the optimal dose of SABER-Bupivacaine for postoperative pain control in patients undergoing hysterectomy on the basis of pharmacokinetics, efficacy and safety evaluations. The study duration consists of a screening period up to 14 days and a treatment period 14 days with a long term follow up visit at 6 months. The study will provide further data on the efficacy and safety of the product.

Critère d'inclusion

• Postoperative pain

Pays

• France
• Germany
• Hungary
• Latvia
• Sweden
• United Kingdom

Liens

• nct